MaD-CLINYC评分:预测住院新冠肺炎患者预后的简单工具。

IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL
Hippokratia Pub Date : 2021-07-01
M V Koutroulos, S A Bakola, S Kalpakidis, D Avramidou, S Panagaris, E Melissopoulou, H Souleiman, A Partsalidis, E Metaxa, I Feresiadis, E Kampaki, V Papadopoulos
{"title":"MaD-CLINYC评分:预测住院新冠肺炎患者预后的简单工具。","authors":"M V Koutroulos,&nbsp;S A Bakola,&nbsp;S Kalpakidis,&nbsp;D Avramidou,&nbsp;S Panagaris,&nbsp;E Melissopoulou,&nbsp;H Souleiman,&nbsp;A Partsalidis,&nbsp;E Metaxa,&nbsp;I Feresiadis,&nbsp;E Kampaki,&nbsp;V Papadopoulos","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Most outcome-predictive models for COVID-19 patients use hospital admission data, offering a spontaneous mortality risk estimation. We aimed to elaborate on a tool that could be applied repeatedly, thus being more suitable for these patients' rapidly changing clinical course.</p><p><strong>Methods: </strong>In this prospective study, we evaluated 560 samples derived from 156 patients hospitalized for COVID-19 in a single center. Age >61 years, male sex, comorbidities >2, need for intensive care unit admission, lactate dehydrogenase (LDH) >408 U/L, Neutrophil/Lymphocyte Ratio (NLR) >17, C-reactive protein (CRP) >10 mg/dl, and D-dimers >3,200 ng/ml were incorporated in an eight-scale score (MaD-CLINYC) after optimal scaling, ridge regression, and bootstrapping, which was documented to correlate with outcome independently of one or more samples analyzed, day from admission at sampling, and need for delivery. Validation process was performed over 574 samples derived from three centers.</p><p><strong>Results: </strong>The developing and the validation cohort Area under Curve (AUC) was 0.90 (95 % Confidence Interval: 0.82-0.98) and 0.91 (0.88-0.94), respectively (p =0.822). A MaD-CLINYC score ≥4 had 75 % sensitivity and 81 % specificity to predict fatal outcome.</p><p><strong>Conclusions: </strong>MaD-CLINYC score is a powerful, feasible, easy-to-use, dynamic tool to assess the risk of the outcome, thus assisting clinicians in close monitoring and timely decisions in COVID-19 hospitalized patients. HIPPOKRATIA 2021, 25 (3):119-125.</p>","PeriodicalId":50405,"journal":{"name":"Hippokratia","volume":"25 3","pages":"119-125"},"PeriodicalIF":0.3000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851139/pdf/hippokratia-25-119.pdf","citationCount":"0","resultStr":"{\"title\":\"The MaD-CLINYC score: An easy tool for the prediction of the outcome of hospitalized COVID-19 patients.\",\"authors\":\"M V Koutroulos,&nbsp;S A Bakola,&nbsp;S Kalpakidis,&nbsp;D Avramidou,&nbsp;S Panagaris,&nbsp;E Melissopoulou,&nbsp;H Souleiman,&nbsp;A Partsalidis,&nbsp;E Metaxa,&nbsp;I Feresiadis,&nbsp;E Kampaki,&nbsp;V Papadopoulos\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Most outcome-predictive models for COVID-19 patients use hospital admission data, offering a spontaneous mortality risk estimation. We aimed to elaborate on a tool that could be applied repeatedly, thus being more suitable for these patients' rapidly changing clinical course.</p><p><strong>Methods: </strong>In this prospective study, we evaluated 560 samples derived from 156 patients hospitalized for COVID-19 in a single center. Age >61 years, male sex, comorbidities >2, need for intensive care unit admission, lactate dehydrogenase (LDH) >408 U/L, Neutrophil/Lymphocyte Ratio (NLR) >17, C-reactive protein (CRP) >10 mg/dl, and D-dimers >3,200 ng/ml were incorporated in an eight-scale score (MaD-CLINYC) after optimal scaling, ridge regression, and bootstrapping, which was documented to correlate with outcome independently of one or more samples analyzed, day from admission at sampling, and need for delivery. Validation process was performed over 574 samples derived from three centers.</p><p><strong>Results: </strong>The developing and the validation cohort Area under Curve (AUC) was 0.90 (95 % Confidence Interval: 0.82-0.98) and 0.91 (0.88-0.94), respectively (p =0.822). A MaD-CLINYC score ≥4 had 75 % sensitivity and 81 % specificity to predict fatal outcome.</p><p><strong>Conclusions: </strong>MaD-CLINYC score is a powerful, feasible, easy-to-use, dynamic tool to assess the risk of the outcome, thus assisting clinicians in close monitoring and timely decisions in COVID-19 hospitalized patients. HIPPOKRATIA 2021, 25 (3):119-125.</p>\",\"PeriodicalId\":50405,\"journal\":{\"name\":\"Hippokratia\",\"volume\":\"25 3\",\"pages\":\"119-125\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2021-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851139/pdf/hippokratia-25-119.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hippokratia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hippokratia","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:大多数新冠肺炎患者的预测结果模型使用住院数据,提供自发的死亡率风险估计。我们旨在详细说明一种可以重复应用的工具,从而更适合这些患者快速变化的临床病程。方法:在这项前瞻性研究中,我们评估了560份样本,这些样本来自一个中心因新冠肺炎住院的156名患者。年龄>61岁,男性,合并症>2,需要入住重症监护室,乳酸脱氢酶(LDH)>408 U/L,中性粒细胞/淋巴细胞比率(NLR)>17,C-反应蛋白(CRP)>10 mg/dl,D-二聚体>3200 ng/ml,在最佳标度、岭回归和自举后纳入八量表评分(MaD CLINYC),其被证明与独立于所分析的一个或多个样本的结果、入院后的第天以及分娩需求相关。对来自三个中心的574个样本进行了验证。结果:发展和验证队列的曲线下面积(AUC)分别为0.90(95%置信区间:0.82-0.98)和0.91(0.88-0.94)(p=0.822)。MaD CLINYC评分≥4对预测死亡结果具有75%的敏感性和81%的特异性。结论:MaD-CLINYC评分是一种功能强大、可行、易于使用、动态的评估结果风险的工具,有助于临床医生密切监测新冠肺炎住院患者并及时做出决定。HIPPOKRATIA 2021,25(3):119-125。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

The MaD-CLINYC score: An easy tool for the prediction of the outcome of hospitalized COVID-19 patients.

The MaD-CLINYC score: An easy tool for the prediction of the outcome of hospitalized COVID-19 patients.

Background: Most outcome-predictive models for COVID-19 patients use hospital admission data, offering a spontaneous mortality risk estimation. We aimed to elaborate on a tool that could be applied repeatedly, thus being more suitable for these patients' rapidly changing clinical course.

Methods: In this prospective study, we evaluated 560 samples derived from 156 patients hospitalized for COVID-19 in a single center. Age >61 years, male sex, comorbidities >2, need for intensive care unit admission, lactate dehydrogenase (LDH) >408 U/L, Neutrophil/Lymphocyte Ratio (NLR) >17, C-reactive protein (CRP) >10 mg/dl, and D-dimers >3,200 ng/ml were incorporated in an eight-scale score (MaD-CLINYC) after optimal scaling, ridge regression, and bootstrapping, which was documented to correlate with outcome independently of one or more samples analyzed, day from admission at sampling, and need for delivery. Validation process was performed over 574 samples derived from three centers.

Results: The developing and the validation cohort Area under Curve (AUC) was 0.90 (95 % Confidence Interval: 0.82-0.98) and 0.91 (0.88-0.94), respectively (p =0.822). A MaD-CLINYC score ≥4 had 75 % sensitivity and 81 % specificity to predict fatal outcome.

Conclusions: MaD-CLINYC score is a powerful, feasible, easy-to-use, dynamic tool to assess the risk of the outcome, thus assisting clinicians in close monitoring and timely decisions in COVID-19 hospitalized patients. HIPPOKRATIA 2021, 25 (3):119-125.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hippokratia
Hippokratia MEDICINE, GENERAL & INTERNAL-
CiteScore
1.10
自引率
0.00%
发文量
0
审稿时长
6-12 weeks
期刊介绍: Hippokratia journal is a quarterly issued, open access, peer reviewed, general medical journal, published in Thessaloniki, Greece. It is a forum for all medical specialties. The journal is published continuously since 1997, its official language is English and all submitted manuscripts undergo peer review by two independent reviewers, assigned by the Editor (double blinded review process). Hippokratia journal is managed by its Editorial Board and has an International Advisory Committee and over 500 expert Reviewers covering all medical specialties and additionally Technical Reviewers, Statisticians, Image processing Experts and a journal Secretary. The Society “Friends of Hippokratia Journal” has the financial management of both the printed and electronic edition of the journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信